Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115308 | 0.94 | REN (0.61) | RENCYP3A4 | |
| SCHEMBL3111643 | 0.94 | REN (0.73) | RENCYP3A4 | |
| SCHEMBL13250040 | 0.92 | REN (0.73) | RENCYP3A4 | |
| SCHEMBL8156701 | 0.92 | REN (0.73) | RENCYP3A4 | |
| SCHEMBL3111636 | 0.92 | REN (0.70) | RENCYP3A4 | |
| SCHEMBL13250037 | 0.91 | REN (0.71) | RENCYP3A4 | |
| SCHEMBL8156699 | 0.91 | REN (0.71) | RENCYP3A4 | |
| SCHEMBL8169760 | 0.91 | REN (0.71) | RENCYP3A4 | |
| SCHEMBL8158661 | 0.90 | REN (0.68) | RENCYP3A4 | |
| SCHEMBL8150780 | 0.90 | REN (0.67) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.